Abstract
Background: Whether HAIR-AN syndrome and polycystic ovarian syndrome (PCOS) are distinct entities or represent a phenotypic spectrum of the same syndrome is still unclear. HAIR-AN syndrome is characterized by high insulin resistance, obesity, and hyperinsulinemia as compared to PCOS and could represent adipose tissue dysfunction as the primary pathophysiologic trigger. This study was undertaken to study the role of adipose tissue dysfunction in HAIR-AN syndrome and PCOS using adipocytokines as surrogate markers of “adiposopathy.” Materials and Methods: A cross-sectional observational study was conducted at a tertiary care hospital over a period of 1 year. Serum adiponectin, leptin, IL-6, and TNF-α levels were measured in 30 women with HAIR-AN syndrome and in 30 women with PCOS. Correlations between adipocytokines, inflammatory markers, serum testosterone, and serum insulin were determined. Data analysis was performed using the SPSS version 23.0 (IBM SPSS Statistics Inc., Chicago, IL, USA) software program. Results: Women with HAIR-AN syndrome had significantly higher hyperandrogenemia, hyperinsulinemia, and insulin resistance as compared to PCOS women. They also had high leptin levels and lower adiponectin levels (p < 0.001). However, the levels of inflammatory markers (TNF-α and IL-6) were similar in both the groups (p > 0.05). Serum adiponectin showed a negative correlation with HOMA-IR and testosterone levels, while leptin showed a positive correlation with both in HAIR-AN patients while no such correlation was found in the PCOS group. Conclusion: The significantly raised adipocytokines in HAIR-AN syndrome patients as compared to PCOS patients indicates the primary role of adipose tissue dysfunction (“adiposopathy”) in the pathogenesis of HAIR-AN syndrome while only a minor role, if any, in PCOS. Both these syndromes stand as distinct entities pathogenically with an overlapping phenotype.
References
1.
Escobar-Morreale
HF
, Carmina
E
, Dewailly
D
, Gambineri
A
, Kelestimur
F
, Moghetti
P
, et al Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society
. Hum Reprod Update
. 2012
Mar-Apr
;18
(2
):146
–70
.
[PubMed]
1355-47862.
Toscano
V
, Balducci
R
, Mangiantini
A
, Falasca
P
, Sciarra
F
. Hyperandrogenism in the adolescent female
. Steroids
. 1998
May-Jun
;63
(5-6
):308
–13
.
[PubMed]
0039-128X3.
Barbieri
RL
, Ryan
KJ
. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features
. Am J Obstet Gynecol
. 1983
Sep
;147
(1
):90
–101
.
[PubMed]
0002-93784.
Rosenfield
RL
. Clinical practice. Hirsutism
. N Engl J Med
. 2005
Dec
;353
(24
):2578
–88
.
[PubMed]
0028-47935.
Barbieri
RL
, Hornstein
MD
. Hyperinsulinemia and ovarian hyperandrogenism. Cause and effect
. Endocrinol Metab Clin North Am
. 1988
Dec
;17
(4
):685
–703
.
[PubMed]
0889-85296.
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
. Hum Reprod
. 2004
;19
(1
):41
–7
. 0268-11617.
Legro
RS
, Arslanian
SA
, Ehrmann
DA
, Hoeger
KM
, Murad
MH
, Pasquali
R
, et al; Endocrine Society
. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline
. J Clin Endocrinol Metab
. 2013
Dec
;98
(12
):4565
–92
.
[PubMed]
0021-972X8.
Héctor
F
. Escobar-Morreale. Polycystic ovarian syndrome: definition, aetiology, diagnosis and treatment
. Nat Rev Endocrinol
. 2018
;14
(5
):270
–84
.
[PubMed]
1759-50299.
Moghetti
P
, Tosi
F
, Bonin
C
, Di Sarra
D
, Fiers
T
, Kaufman
JM
, et al Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome
. J Clin Endocrinol Metab
. 2013
Apr
;98
(4
):E628
–37
.
[PubMed]
0021-972X10.
Escobar-Morreale
HF
. Reproductive endocrinology: menstrual dysfunction—a proxy for insulin resistance in PCOS?
Nat Rev Endocrinol
. 2014
Jan
;10
(1
):10
–1
.
[PubMed]
1759-502911.
Barbieri
RL
, Smith
S
, Ryan
KJ
. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism
. Fertil Steril
. 1988
Aug
;50
(2
):197
–212
.
[PubMed]
0015-028212.
Escobar-Morreale
HF
, Luque-Ramírez
M
, San Millán
JL
. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome
. Endocr Rev
. 2005
Apr
;26
(2
):251
–82
.
[PubMed]
0163-769X13.
Vink
JM
, Sadrzadeh
S
, Lambalk
CB
, Boomsma
DI
. Heritability of polycystic ovary syndrome in a Dutch twin-family study
. J Clin Endocrinol Metab
. 2006
Jun
;91
(6
):2100
–4
.
[PubMed]
0021-972X14.
Azziz
R
. PCOS in 2015: new insights into the genetics of polycystic ovary syndrome
. Nat Rev Endocrinol
. 2016
Feb
;12
(2
):74
–5
.
[PubMed]
1759-502915.
Dumesic
DA
, Abbott
DH
, Padmanabhan
V
. Polycystic ovary syndrome and its developmental origins
. Rev Endocr Metab Disord
. 2007
Jun
;8
(2
):127
–41
.
[PubMed]
1389-915516.
Filippou
P
, Homburg
R
. Is foetal hyperexposure to androgens a cause of PCOS?
Hum Reprod Update
. 2017
Jul
;23
(4
):421
–32
.
[PubMed]
1355-478617.
Rutkowska
AZ
, Diamanti-Kandarakis
E
. Polycystic ovary syndrome and environmental toxins
. Fertil Steril
. 2016
Sep
;106
(4
):948
–58
.
[PubMed]
0015-028218.
Escobar-Morreale
HF
, Samino
S
, Insenser
M
, Vinaixa
M
, Luque-Ramírez
M
, Lasunción
MA
, et al Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS
. Clin Chem
. 2012
Jun
;58
(6
):999
–1009
.
[PubMed]
0009-914719.
Bastard
JP
, Maachi
M
, Lagathu
C
, Kim
MJ
, Caron
M
, Vidal
H
, et al Recent advances in the relationship between obesity, inflammation, and insulin resistance
. Eur Cytokine Netw
. 2006
Mar
;17
(1
):4
–12
.
[PubMed]
1148-549320.
Hsu
WC
, Araneta
MR
, Kanaya
AM
, Chiang
JL
, Fujimoto
W
. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening
. Diabetes Care
. 2015
Jan
;38
(1
):150
–8
.
[PubMed]
0149-599221.
Pandžić Jakšić
V
, Grizelj
D
. Under the surface of subcutaneous adipose tissue biology
. Acta Dermatovenerol Croat
. 2016
Dec
;24
(4
):250
–60
.
[PubMed]
1847-653822.
Sniderman
AD
, Bhopal
R
, Prabhakaran
D
, Sarrafzadegan
N
, Tchernof
A
. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis
. Int J Epidemiol
. 2007
Feb
;36
(1
):220
–5
.
[PubMed]
0300-577123.
Saxena
A
, Tiwari
P
, Wahi
N
, Soni
A
, Bansiwal
RC
, Kumar
A
, et al Transcriptome profiling reveals association of peripheral adipose tissue pathology with type-2 diabetes in Asian Indians
. Adipocyte
. 2019
Dec
;8
(1
):125
–36
.
[PubMed]
2162-394524.
Mathur
SK
, Jain
P
, Mathur
P
, Punjabi
P
, Agarwal
A
, Sharma
A
. Transcriptomic analysis of visceral adipose from healthy and diabetic obese subjects
. Indian J Endocrinol Metab
. 2013
May
;17
(3
):446
–50
.
[PubMed]
2230-821025.
Kumar
A
, Tiwari
P
, Saxena
A
, Purwar
N
, Wahi
N
, Sharma
B
, et al The Transcriptomic Evidence on the Role of Abdominal Visceral vs. Subcutaneous Adipose Tissue in the Pathophysiology of Diabetes in Asian Indians Indicates the Involvement of Both
. Biomolecules
. 2020
Aug
;10
(9
):E1230
.
[PubMed]
2218-273X26.
Koerner
A
, Kratzsch
J
, Kiess
W
. Adipocytokines: leptin—the classical, resistin—the controversical, adiponectin—the promising, and more to come
. Best Pract Res Clin Endocrinol Metab
. 2005
Dec
;19
(4
):525
–46
.
[PubMed]
1521-690X27.
Rasouli
N
, Kern
PA
. Adipocytokines and the metabolic complications of obesity
. J Clin Endocrinol Metab
. 2008
Nov
;93
(11
Suppl 1
):S64
–73
.
[PubMed]
0021-972X28.
Ouchi
N
, Ohashi
K
, Shibata
R
, Murohara
T
. Adipocytokines and obesity-linked disorders
. Nagoya J Med Sci
. 2012
Feb
;74
(1-2
):19
–30
.
[PubMed]
0027-762229.
Cao
H
. Adipocytokines in obesity and metabolic disease
. J Endocrinol
. 2014
Jan
;220
(2
):T47
–59
.
[PubMed]
0022-079530.
Ouchi
N
, Walsh
K
. A novel role for adiponectin in the regulation of inflammation
. Arterioscler Thromb Vasc Biol
. 2008
Jul
;28
(7
):1219
–21
.
[PubMed]
1079-564231.
Kadowaki
T
, Yamauchi
T
, Kubota
N
, Hara
K
, Ueki
K
, Tobe
K
. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
. J Clin Invest
. 2006
Jul
;116
(7
):1784
–92
.
[PubMed]
0021-973832.
Weyer
C
, Funahashi
T
, Tanaka
S
, Hotta
K
, Matsuzawa
Y
, Pratley
RE
, et al Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia
. J Clin Endocrinol Metab
. 2001
May
;86
(5
):1930
–5
.
[PubMed]
0021-972X33.
Turpeinen
AK
, Haffner
SM
, Louheranta
AM
, Niskanen
LK
, Miettinen
H
, Uusitupa
MI
. Serum leptin in subjects with impaired glucose tolerance in relation to insulin sensitivity and first-phase insulin response
. Int J Obes Relat Metab Disord
. 1997
Apr
;21
(4
):284
–7
.
[PubMed]
34.
Barzilai
N
, Wang
J
, Massilon
D
, Vuguin
P
, Hawkins
M
, Rossetti
L
. Leptin selectively decreases visceral adiposity and enhances insulin action
. J Clin Invest
. 1997
Dec
;100
(12
):3105
–10
.
[PubMed]
0021-973835.
Couillard
C
, Mauriège
P
, Imbeault
P
, Prud’homme
D
, Nadeau
A
, Tremblay
A
, et al Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia
. Int J Obes Relat Metab Disord
. 2000
Jun
;24
(6
):782
–8
.
[PubMed]
36.
Bastard
JP
, Maachi
M
, Van Nhieu
JT
, Jardel
C
, Bruckert
E
, Grimaldi
A
, et al Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro
. J Clin Endocrinol Metab
. 2002
May
;87
(5
):2084
–9
.
[PubMed]
0021-972X37.
Tilg
H
, Moschen
AR
. Inflammatory mechanisms in the regulation of insulin resistance
. Mol Med
. 2008
Mar-Apr
;14
(3-4
):222
–31
.
[PubMed]
1076-155138.
Skalicky
J
, Muzakova
V
, Kandar
R
, Meloun
M
, Rousar
T
, Palicka
V
. Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome
. Clin Chem Lab Med
. 2008
;46
(4
):499
–505
.
[PubMed]
1434-662139.
Bahceci
M
, Gokalp
D
, Bahceci
S
, Tuzcu
A
, Atmaca
S
, Arikan
S
. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults?
J Endocrinol Invest
. 2007
Mar
;30
(3
):210
–4
.
[PubMed]
0391-409740.
Carmina
E
, Ferin
M
, Gonzalez
F
, Lobo
RA
; Carmina E1
. Ferin M, Gonzalez F, Lobo RA. Evidence that insulin and androgens may participate in the regulation of serum leptin levels in women
. Fertil Steril
. 1999
Nov
;72
(5
):926
–31
. 0015-028241.
Ferriman
D
, Gallwey
JD
. Clinical assessment of body hair growth in women
. J Clin Endocrinol Metab
. 1961
Nov
;21
(11
):1440
–7
.
[PubMed]
0021-972X42.
Pochi
PE
, Shalita
AR
, Strauss
JS
, et al Report of the consensus conference on Acne Cassification, Washington, DC, USA March 24-25, 1990
. J Am Acad Dermatol
. 1991
;24
:495
–500
.
[PubMed]
0190-962243.
Burke
JP
, Hale
DE
, Hazuda
HP
, Stern
MP
. A quantitative scale of acanthosis nigricans
. Diabetes Care
. 1999
Oct
;22
(10
):1655
–9
.
[PubMed]
0149-599244.
Matthews
DR
, Hosker
JP
, Rudenski
AS
, Naylor
BA
, Treacher
DF
, Turner
RC
. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
. Diabetologia
. 1985
Jul
;28
(7
):412
–9
.
[PubMed]
0012-186X45.
Lindholm
A
, Blomquist
C
, Bixo
M
, Dahlbom
I
, Hansson
T
, Sundström Poromaa
I
, et al No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls
. Hum Reprod
. 2011
Jun
;26
(6
):1478
–85
.
[PubMed]
0268-116146.
Carmina
E
, Chu
MC
, Moran
C
, Tortoriello
D
, Vardhana
P
, Tena
G
, et al Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome
. Fertil Steril
. 2008
Mar
;89
(3
):642
–8
.
[PubMed]
0015-028247.
Svendsen
PF
, Christiansen
M
, Hedley
PL
, Nilas
L
, Pedersen
SB
, Madsbad
S
. Adipose expression of adipocytokines in women with polycystic ovary syndrome
. Fertil Steril
. 2012
Jul
;98
(1
):235
–41
.
[PubMed]
0015-0282© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
